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BACKGROUND
Diabetic nephropathy is a significant contributor to the morbidity, mortality and health care cost among patients with 
diabetes. With increasing understanding of this problem, the natural progression of diabetic nephropathy can potentially 
be changed.
OBJECTIVE
This article examines the natural history of diabetic nephropathy and provides guidelines on detection, management  
and future treatment possibilities of this complication.
DISCUSSION 
Prevention and slowing progression are the most important aspects of the management of diabetic nephropathy.  
This involves monitoring renal function and risk factors for renal damage and early active intervention. The angiotensin 
converting enzyme inhibitors and receptor antagonists are important components of therapy, both for controlling 
hypertension and for slowing the progression of micro and macroalbuminuria. When microalbuminuria occurs, intensive 
intervention on a range of risk factors can halve the number of those suffering a cardiovascular event or progressing to 
macroalbuminuria. When renal insufficiency occurs, particularly when creatinine clearance is <30 mL/minute, referral to 
an nephrologist should be considered.
Micro- and macro-albuminuria occur in 25 and 5% 
of Australian adults with diabetes.1 In a general 
practice of 1000 active patients, 40 will have known 
diabetes and 12 of these (30%) will have nephropathy.2 
In terms of life years lost for those with diabetes, 
kidney disease ranks second to cardiovascular 
disease. In terms of cost to the health care 





both	 in	 absolute	 numbers	 and	 as	 a	 percentage	 of	 the	
total.4,5	 If	 current	 trends	 continue,	 renal	 replacement	
for	 people	 with	 diabetes	 will	 be	 a	 major	 burden	 on	
the	Australian	 health	 care	 system.	 In	many	 developed	
countries,	 including	 Australia,	 diabetic	 nephropathy,	
mostly	 associated	with	 type	 2	 diabetes,	 has	 overtaken	
glomerulonephritis	as	the	leading	cause	of	end	stage	renal	
failure.	Recent	 trials	have	shown	 that	 the	kidneys	can	be	
protected	and	patient	outcomes	improved.	
Natural history
The	 earliest	 clinical	 evidence	 of	 nephropathy	 is	 the	
appearance	 of	 microalbuminuria	 (≥30	 mg/day	 or	 ≥20	
µg/min).	A	 higher	 proportion	 of	 individuals	with	 type	 2	
diabetes	 are	 found	 to	 have	microalbuminuria	 and	 overt	
nephropathy	 shortly	 after	 diagnosis,	 because	 in	 type	 2	
diabetes	the	metabolic	abnormality	may	have	been	present	
for	years	before	diagnosis.
	 Extrapolating	 from	 the	United	 Kingdom	Prospective	
Diabetes	 Study	 (UKPDS)6	 data,	 in	 a	 population	 of	 9900	
patients	 with	 type	 2	 diabetes,	 it	 is	 estimated	 that	
approximately	 7000	 have	 normoalbuminuria,	 2000	 have	





•	2%	 (each	 year)	 of	 patients	without	 albuminuria	with	
progression	to	microalbuminuria	
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macroalbuminuria,	and	
•	2.5%	with	macroalbuminuria	 progress	 to	 end	 stage	
renal	failure.7	
The	UKPDS	also	showed	 that	annual	death	 rates	and	 the	
risk	of	cardiovascular	death	 increased	with	 the	 increasing	




	 Once	macroalbuminuria	 sets	 in,	 glomerular	 filtration	
rate	 (GFR)	 starts	 to	 fall	 at	 variable	 rates	 (2–20	mL/min/yr	
depending	 on	 factors	 such	 as	 blood	 pressure).8	 Patients	
with	 both	 type	 2	 diabetes	 and	microalbuminuria	 are	 at	
increased	risk	of	premature	death	and	four	times	as	likely	
as	 those	with	 normoalbuminuria	 to	 die	 prematurely	 of	 a	
cardiovascular	 event.9,10	The	 8	 year	 risk	 of	 cardiovascular	
events	 is	 44%	 in	 patients	 in	whom	 risk	 factors	 are	 not	
actively	controlled.11
Risk factors
Heredity,	 race,	 age,	 duration	 of	 diabetes	 and	 impaired	
renal	 function	 are	 risk	 factors	 that	 are	 not	modifiable	





	 The	UKPDS	 showed	 that	 decreases	 in	 blood	 glucose	
and	systolic	blood	pressure	were	associated	with	decreases	
in	 the	 occurrence	 and	 progression	 of	microalbuminuria	









In	 the	 past,	 detection	 of	 early	 diabetic	 nephropathy	was	




(positive	 on	 routine	 dipstick	 analysis)	 or	 the	 plasma	
creatinine	was	elevated,	 renal	 damage	was	 considerable,	
irreversible	and	often	relentlessly	progressive.
	 The	 development	 of	 sensitive	 assays	 for	 albumin	
has	 allowed	 early	 detection	 of	 glomerular	 damage	 at	 a	
time	when	 intervention	may	 be	 effective.	The	 current	
recommendation	 is	 that	 all	 patients	with	 type	2	diabetes	
be	tested	annually	for	microalbuminuria.	This	can	be	done	
on	 the	 first	 voided	morning	 urine	 sample	 or	 in	 a	 timed	
over	 night	 urine	 collection.	 Microalbuminuria	 should	
be	 confirmed	 and	 if	 the	 second	 test	 is	 negative	 a	 third	
deciding	test	done.	Microalbuminuria	is	defined	in	Table 2.
	 Screening	should	not	be	performed	in	the	presence	of	




	 Although	measuring	microalbuminuria	 is	 useful	 in	
detecting	 early	 diabetic	 nephropathy,	 some	patients	may	
have	impaired	renal	function	for	other	reasons	(decreased	























Conventional BP 10/5 HbA1c 1% Both
Figure 2. Lessons from UKPDS
% progression from normo- to micro-albuminuria over 6 years 
with reduction in: BP by 10/5 mmHg; A1C by 1%; or both










 Distribution of 9000 adults with type 2 diabetes
 Number % progressing to the next stage each year
Mortality % dying each year
Figure 1. Natural history of nephropathy
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Targeting protection
The	 basis	 for	 prevention	 is	 the	 treatment	 of	 known	




Intensive	 blood	 glucose	 and	 blood	 pressure	 control	 are	
the	 cornerstones	 of	 reducing	 the	 risk	 of	 development	 of	
microalbuminuria.	This	 is	 supported	by	 the	evidence	 from	
the	UKPDS	study	(Figure 2).6,12	The	decline	of	GFR	increases	
by	1	mL/min/yr	with	each	2	mmHg	increase	in	mean	arterial	
pressure;	 cardiovascular	mortality	 increases	 by	 30%	 for	
each	10	mmHg	increase	in	systolic	blood	pressure.	
	 Beware	 of	medications	 that	 can	 damage	 the	 kidneys	
(Table 4)	 and	 in	 particular	 of	 the	 ‘triple	 whammy’	 of	
nonsteroidal	 anti-inflammatory	 drugs	 (NSAID),	 diuretic	
and	 angiotensin	 converting	 enzyme	 (ACE)	 inhibitors	 or	





to	 review	 the	 patient	 carefully	 for	 other	 risk	 factors	 for	
macrovascular	 disease.	 Finding	microalbuminuria	may	
renew	 your	 enthusiasm	 and	 your	 patient’s	motivation	 to	
modify	 cardiovascular	 risk	 factors.	 In	 this	group	 there	are	
two	main	goals.	First	 to	 reduce	 the	 risk	of	 cardiovascular	
events	 and	 second	 to	 slow	 the	 progression	 from	micro-	
to	macro-albuminuria	 and	 the	decline	of	 renal	 function	 in	
patients	with	macroalbuminuria.
	 When	microalbuminuria	 is	 present	 cardiovascular	 risk	
factors	ought	to	be	treated	actively.	Aim	to	get	the	ABCss	
on	target	(Table 3).	The	STENO-2	study	showed	that	active	
multifactorial	 intervention	 targeting	 the	ABCss	halves	 the	
number	of	cardiovascular	events	and	the	progression	from	
micro-	to	macro-albuminuria16	(Figure 3).
	 Renin	 angiotensin	 system	 blockade	 with	 an	 ACE	
inhibitor	 or	ARA	 is	 reno-protective	 independent	 of	 blood	
pressure	 reduction.	 Angiotensin	 converting	 enzyme	
inhibitors	 or	ARAs	 are	 recommended	 for	 patients	with	
type	 2	 diabetes	 and	microalbuminuria	 even	 if	 they	 are	
normotensive.2	The	PRIME	 studies	 showed	 that	 the	 use	
of	an	ARA	 (irbesartan)	 in	patients	with	micro-	and	macro-
albuminuria	is	associated	with	decreased	progression	from	
micro-	 to	macro-albuminuria	 and	 of	macroalbuminuria	 to	
end	stage	renal	failure,	cardiovascular	events	or	death.17,18	
	 An	 acute	 rise	 in	 serum	 creatinine	 of	 up	 to	 20%,	
stabilising	 after	 2	months,	might	 occur	 in	 proteinuric	
patients	 with	 creatinine	 values	 exceeding	 120	 µmol/L	
starting	 on	 an	 ACE	 inhibitor	 or	 ARA.	 Nonetheless	
ACE	 inhibitors	 and	ARA	 are	 associated	with	 long	 term	
preservation	of	 renal	 function	 and	 should	 be	 continued.19	
Greater	 increases	 should	 raise	 the	 suspicion	 of	 renal	
artery	 stenosis.	After	 commencing	 an	ACE	 inhibitor	 or	
ARA,	 creatinine	 and	potassium	should	be	 checked	within	
7–10	days	of	 starting	 and	 at	 least	 6–12	monthly	 intervals	
during	treatment.	
Patients with early renal insufficiency
Early	renal	insufficiency,	defined	as	a	calculated	or	measured	
GFR	between	30–60	mL/min	 per	 1.73	m2,	 is	 a	 common	
yet	 under-recognised	problem	 in	Australia.	Many	of	 these	
patients	 have	 normal	 serum	 creatinine	 concentrations.	
Calculating	the	GFR,	using	formula	such	as	the	abbreviated	
MDRD	 (named	after	Modification	of	Diet	 in	Renal	Disease	
Study)	 equation	 (Table 5),	 is	 useful	 in	 identifying	patients	
with	 early	 renal	 insufficiency.20	Pathology	 laboratories	will	
calculate	 and	 report	 an	estimated	GFR	using	 this	 formula	
with	requests	for	serum	creatinine.21
	 Strategies	 to	 slow	 the	 progression	 of	 early	 renal	
insufficiency	 are	 similar	 to	management	 of	 patients	with	
Table 2. Definitions of microalbuminuria
Albumin-creatinine ratio (ACR)
• women 3.5–35.0 mg/mmol
• men 2.5–25.0 mg/mmol
Albumin excretion rate  20–200 µg/min






* <125/75 if proteinuria >1 g/day exists




















Figure 3. Lessons from STENO-2
Progression to cardiovascular event or nephropathy with 
conventional/intensive treatment (CT/IT)
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As	 noted	 earlier,	 microalbuminuria	 in	 someone	 with	
diabetes	 is	 likely	 but	 not	 necessarily	 caused	by	diabetes.	
The	finding	of	microalbuminuria	should	prompt	review	for	
other	 expected	microvascular	 complications	 (especially	
retinopathy)	 and	 consideration	 of	 other	 possible	 causes	
(eg.	IGA	nephropathy).	If	there	is	any	suspicion	of	a	cause	




confirmation	 of	 diagnosis,	 delay	 progression	 of	 renal	
impairment,	 and	 other	 complications,	 patient	 education,	
preparation	 for	 dialysis	 and	 possibly	 improved	 survival	
and	morbidity.
Managing later stages of renal failure
In	 general,	when	 creatinine	 clearance	 drops	 to	 less	 than	
30	mL/min	 all	 patients	 should	 be	 considered	 for	 referral	
to	a	nephrologist.	In	patients	with	advanced	diabetic	renal	
failure	 several	 specific	 points	 of	management	 should	 be	
followed.	Nephrotoxic	 agents	 such	 as	X-ray	 contrast	 and	
NSAID	 should	 be	 avoided.	Metformin,	which	may	 cause	
lactic	acidosis,	should	also	be	avoided.	When	haemoglobin	
levels	 drop	 to	 100	g/dL,	 erythropoietin	 therapy	 should	be	
considered.	When	systemic	acidosis	develops	bicarbonate	
therapy	 (840	mg	 capsules,	 1–2	 times	 per	 day)	 can	 be	
considered,	 remembering	 the	 risk	 of	 fluid	 retention	 and	
exacerbation	 of	 hypertension.	Other	 beneficial	 effects	 of	
bicarbonate	therapy	include	correction	of	hyperkalaemia.	
	 In	 the	 very	 late	 stages	 of	 renal	 failure	 or	 in	 those	
with	 severe	 uraemic	 symptoms,	 dietary	 protein	
restriction	 is	 considered,	 however	 the	 MDRD	 study	
showed	 that	 protein	 restriction	 at	 best	 improved	
t ime	 off	 dialysis	 by	 approximately	 6	 months.22	
Generally	 patients	 with	 end	 stage	 renal	 disease	
(ESRD)	 from	 diabetes	 mellitus	 will	 be	 considered	
for	 starting	 dialysis	 at	 higher	 creatinine	 clearance	 (or	
lower	 serum	 creatinine	 levels)	 than	 patients	with	 other	
causes	of	ESRD.	
	 The	 decision	 regarding	 dialysis	 treatment	modality	
is	made	 on	 an	 individual	 basis.	 In	 general,	 patients	with	
ESRD	 from	 diabetes	 are	more	 likely	 to	 have	 peripheral	
vascular	 disease	 and	 are	 at	 greater	 risk	 of	 developing	
steal	 syndromes	 in	 the	 hands	 as	 a	 consequence	 of	 an	
arteriovenous	 fistula.	 Furthermore,	 patients	with	 diabetic	
ESRD	 are	more	 likely	 to	 have	 cardiac	 disease	 and	 are	
at	 greater	 risk	 of	 developing	worsening	 cardiac	 failure	
in	 association	with	 large	 fluid	 shifts	 of	 haemodialysis.	
Therefore,	 peritoneal	 dialysis	with	 its	 gentler	 fluid	 shifts,	
preservation	 of	 residual	 renal	 function	 and	 avoidance	 of	
vascular	 access,	 is	 often	 been	 the	 preferred	means	 of	
dialysis	therapy	in	diabetic	patients.
	 Renal	 transplantation	 is	 a	 viable	 option	 for	 patients	
with	 ESRD	 due	 to	 diabetes.	 Survival	 of	 patients	with	 a	
renal	 transplant	 is	superior	 to	 those	 remaining	on	dialysis	
and	 should	 be	 considered	whenever	 possible.	As	many	
patients	with	 diabetic	 nephropathy	 are	 older,	 they	 are	
less	 likely	 to	 be	 transplantation	 candidates.	 Pancreatic	 or	
combined	kidney-pancreas	transplantation	 is	an	option	for	




severe	 chronic	 renal	 insufficiency	may	be	 renoprotective.	
Table 5. Calculating GFR
The MDRD equation:
GFR = 186 x {[serum creatinine (µmol/L)/88.4]1.154} x (age)-0.203 x (0.742 if female) 
x (1.210 if Afro American)
An automated calculator for MDRD may be found at http://kidney.org.au 
Table 4. The nine nephropathic nasties
Nephrotoxic 
Radiocontrast agents – low ionic agents, avoid dehydration
NSAID* – use paracetamol
ACE inhibitors – check renal function
Needs adjustment if GFR is reduced 
Allopurinol – 100 mg/day per 30 mL/min of GFR
Digoxin – check levels
Sulphonamides – half dosage if GFR is <30 mL/min
Not used if GFR <30 mL/min 
Some hypoglycaemics – glibenclamide, glimepiride, metformin
Potassium sparing diuretics – amiloride, triamterene, spironolactone
Tetracyclines
* including COX-2 ‘specific’ NSAID
Table 6. Indications for referral
•   Advanced renal disease (calculated GFR <30 mL/min,  
proteinuria >3 g/24 hours)
•  Glomerular haematuria
•  Rapid decline in GFR (>10 mL/min/yr)
•  Anaemia (haemoglobin <120 g/L)
•  Difficult to control hyperglycaemia, hypertension or dyslipidaemia
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Current	 randomised	 controlled	 trials	 such	 as	Anaemia	
CORrection	 in	 Diabetes	 (ACORD)	 are	 assessing	 if	
erythropoietin	has	a	renoprotective	action.23
	 Evidence	 is	 emerging	 that	 newer	 treatments	 such	 as	
glycosaminoglycans	 (eg.	 sulodexide),24	 aldose	 reductase	






with	 a	 poor	 prognosis.	 However,	 we	 now	 understand	
the	 contributors	 to	 diabetic	 nephropathy	 and	 there	 are	
new	methods	 for	 early	 detection,	medications	 to	 delay	
progression,	 and	 technologies	 for	 the	management	 of	
renal	 failure.	The	 general	 practitioner	 plays	 a	 strategic	
role	 in	 delaying	 and	 preventing	 diabetic	 nephropathy	
by	 coordinating	 and	 overseeing	 the	 multifactorial,	
multidisciplinary	interventions.
Resources
•  CARI guidelines: Caring for Australians with renal impairment. 
Available at www.kidney.org.au/cari
•  New Zealand Guidelines Group: Primary care guidelines for the 
management of core aspects of diabetes care. Available at www.
nzgg.org.nz/library/gl_complete/diabetes/index.cfm#contents
•  National Heart Foundation of Australia: Guide to management of 
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